<DOC>
	<DOCNO>NCT00500331</DOCNO>
	<brief_summary>This dose-ranging study evaluate efficacy , safety tolerability range dose investigational product pioglitazone , compare placebo , administer monotherapy 12 week treatment naive patient T2DM</brief_summary>
	<brief_title>Dose-Ranging Study Treatment Naive Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Inclusion criterion : Subjects document diagnosis T2DM HbA1c level Visit 1 ≥7.0 % ≤9.5 % measured central laboratory . Subjects HbA1c &lt; 7.5 % must fast fingerstick glucose ≥7 mmol/L ( 126 mg/dL ) Week 0 prior randomization . Subjects treatmentnaïve take insulin , oral injectable antidiabetic medication past 3 month take glucose lower agent ≥4 week time past , Subjects newly diagnose treat diet exercise minimum 6 week Subjects 18 70 year age inclusive time Screening . Females nonchildbearing childbearing potential eligible participate follow : Women childbearing potential must willing use one follow contraception method : intrauterine device , condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent least 30 day prior start study medication , throughout study followup visit . Note : use oral contraceptive permit . Women nonchild bear potential defined follow : female regardless age , function ovary current document tubal ligation [ Hatcher , 2004 ] bilateral oophorectomy total hysterectomy , female postmenopausal ) . ( Postmenopausal define one year without menses appropriate clinical profile , e.g . age appropriate , &gt; 45 year , absence hormone replacement therapy . In addition criterion , postmenopausal status still questionable , blood sample draw simultaneous measurement follicle stimulate hormone estradiol ; value consider confirm postmenopausal state respectively : FSH &gt; 40 MIU/mL estradiol &lt; 40pg/mL ( &lt; 140 pmol/L ) ) . Informed Consent : sign date write consent must obtain subject procedure perform . Metabolic Disease Diagnosis Type 1 diabetes mellitus . History ketoacidosis require hospitalization . Thyroid disorder [ TSH low limit reference range ( LLRR ) 0.4mIU/L upper limit reference range ( ULRR ) &gt; 5.5 mIU/L Screening ] . Hypothyroidism treat dose regimen thyroid hormone replacement least 3 month prior Screening allow . BMI &lt; 22 &gt; 43 kg/m2 . Significant weight gain loss ( define &gt; 5 % total body weight ) 3 month prior Screening . Diabetic Medication Has take insulin oral injectable antidiabetic medication ≥4 week time prior screen . Has take insulin oral injectable antidiabetic medication within 3 month screen . Cardiovascular Disease Recent history presence clinically significant acute cardiovascular disease include : 1 . Documented myocardial infarction 6 month prior Screening . 2 . Coronary revascularization include percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) surgery either plan and/or occur 6 month prior Screening . 3 . Unstable angina 6 month prior Screening . 4 . Clinically significant supraventricular arrhythmia require medical therapy , history nonsustained sustained ventricular tachycardia . Symptomatic valvular heart disease valvular heart disease require therapy endocarditis prophylaxis . 5 . Congestive heart failure ( CHF , New York Heart Association ( NYHA ) Class II IV ) require pharmacologic treatment . NYHA Class I may include accordance local prescribe information pioglitazone . 6 . Blood pressure ( BP ) &gt; 150/100mmHg . If subject receiving permit antihypertensive therapy , must stable dose ( ) therapy least 4 week prior Screening . 7 . Has QTc interval ( Bazett 's ) ≥450msec Screening single ECG average value 3 ECGs take 5 minute apart ( local reading ECG ) . 8 . Other clinically significant ECG abnormality , opinion investigator , may affect interpretation efficacy safety data , otherwise contraindicate participation clinical trial new chemical entity . Fasting triglyceride ≥400mg/dL ( 4.56mmol/L ) Screening . If subject receiving permit lipidlowering therapy , must stable dose ( ) therapy least 6 week prior Screening . Niacin bile acid sequestrants prohibit . Hepatic Disease Has diagnosis active hepatitis ( hepatitis B surface antigen hepatitis C antibody ) , clinically significant hepatic enzyme elevation include : Any one following enzymes great 2 time upper limit reference range ( ULRR ) value Screening . alanine transaminase ( ALT ) . aspartate transaminase ( AST ) . alkaline phosphatase ( AP ) . Has total bilirubin level &gt; 1.5 time ULRR Screening exception suspect confirm Gilbert 's disease . Pancreatic Disease Secondary cause diabetes : history chronic acute pancreatitis Renal Disease Significant renal disease Screening manifest : Glomerular filtration rate ( GFR ) &lt; 60mL/min ( estimate serum creatinine Visit 1 demographic data use MDRD equation ) .For MDRD equation , please refer study procedure manual . Proteinuria ≥1+ urinary dipstick Recurrent genitourinary tract infection define ≥2 episode complicate uncomplicated cystitis pyelonephritis 6 month prior Screening A positive qualitative urinary dipstick leukocyte , red blood cell ( RBC ) nitrites Screening . Concurrent Disease Has concurrent condition clinically significant abnormality identify screen physical examination , laboratory test ( include blood electrolyte ) , electrocardiogram , include pulmonary , neurological inflammatory disease , , opinion investigator , may affect interpretation efficacy safety data , otherwise contraindicate participation clinical trial new chemical entity History significant comorbid disease active 6 month prior Screening ( e.g. , cholecystitis , acute pancreatitis , gastrointestinal disease , chronic diarrhea , etc . ) Has history malignancy within past five year [ superficial squamous cell carcinoma noninvasive pathology basal cell carcinoma successfully treat local excision ] cervical cancer situ treat definitively least 6 month prior Screening Concurrent Medication Is currently take take follow medication 8 week prior Screening : 1 . Digoxin 2 . Warfarin oral anticoagulant ( aspirin nonsteroidal antiinflammatory drug permit ) 3 . Bile acid sequestrants 4 . Niacin ( exclude routine vitamin supplementation ) 5 . Antiobesity agent ( include fat absorption block agent ) 6 . Oral injectable corticosteroid ( inhale intranasal corticosteroid permit ) 7 . Loop diuretics 8 . Monoamine oxidase inhibitor tricyclic amine 9 . Antiretroviral drug 10 . St John 's Wort 11 . Oral chromium Pregnancy &amp; Breast Feeding Is currently lactate pregnant Other Current smoker unable abstain smoking clinic visit Has history alcohol substance abuse within past year Screening alcohol substance abuse treatment , determine investigator : Unwilling refrain use illicit drug adhere protocolstated restriction participate study . Has average weekly intake great 21 unit average daily intake great 3 unit ( male ) average weekly intake great 14 unit average daily intake great 2 unit ( female ) . One unit equivalent halfpint beer 1 measure spirit 1 glass wine Has participate study investigational market drug 3 month prior Screening In opinion investigator risk noncompliance study procedure , read , understand , complete study related material , particularly informed consent Known allergy tablet excipients , history drug allergy , , opinion responsible study physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pioglitazone</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Diabetes mellitus</keyword>
</DOC>